Investment analysts at Jefferies Group increased their target price on shares of Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) from $15.00 to $16.00 in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the stock.

The analysts wrote, “NPSP now has WW rights to its two proprietary products – teduglutide and rPTH – by buying back Revestive and Natpara/Proteact from Takeda for $50M upfront in its shares (6.8% dilution). We now assume ~$150M peak EU sales for Revestive (vs. ~$300M in US Gattex sales), which we view as accretive transaction in out years. Initial Gattex prescription (72 Rx to date) is encouraging while still early.”

Shares of Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) opened at 9.88 on Wednesday. Nps Pharmaceuticals Incorporated has a 52 week low of $6.32 and a 52 week high of $11.22. The stock’s 50-day moving average is currently $8.36. The company’s market cap is $858.7 million.

Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) last posted its quarterly earnings results on Thursday, February 21st. The company reported ($0.14) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.09) by $0.05. The company had revenue of $27.10 million for the quarter, compared to the consensus estimate of $28.93 million. During the same quarter last year, the company posted ($0.10) earnings per share. Nps Pharmaceuticals Incorporated’s revenue was up 3.2% compared to the same quarter last year. Analysts expect that Nps Pharmaceuticals Incorporated will post $-0.18 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on NPSP. Analysts at Canaccord Genuity raised their price target on shares of Nps Pharmaceuticals Incorporated from $16.00 to $20.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Brean Murray downgraded shares of Nps Pharmaceuticals Incorporated from a “buy” rating to a “hold” rating in a research note to investors on Tuesday. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Nps Pharmaceuticals Incorporated in a research note to investors on Friday, February 22nd. They set a “buy” rating and a $20.00 price target on the stock.

Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $15.67.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a biopharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders and medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.